Neobe Raises $6.8 Million To Advance Engineered Bacteria For Solid Tumors

Neobe Therapeutics has raised $6.8 million in seed financing to advance engineered bacterial medicines designed to break down physical barriers that can prevent cancer treatments from reaching solid tumors. ARC Ventures led the round. Faber, Macmillan Ventures, Proven Connect, and Empirical Ventures participated alongside existing investor 2048 Ventures. The financing brings Neobe’s total funding to more than $10.5 million.

Neobe plans to use the capital to advance its lead program, NEO22, through preclinical development and toward an investigational new drug filing in 2028. The company will also strengthen its leadership team as it prepares to move its technology toward clinical testing.

An additional tranche of the seed round is expected to finance an initial human study.

Breaking Down The Tumor Microenvironment

Immunotherapies and other modern cancer medicines have improved treatment for many patients, but their effectiveness can be limited when drugs or immune cells cannot enter a tumor.

Some solid tumors are surrounded by a dense, fibrous matrix. This physical structure can function as a barrier, preventing therapeutic agents and immune cells from reaching cancer cells even when the treatment has an appropriate biological target.

Neobe is engineering harmless strains of common bacteria into programmable living medicines. After injection, the bacteria are intended to travel to tumors and release enzymes that dissolve components of the surrounding matrix.

The goal is not necessarily to kill cancer cells directly. Instead, Neobe’s technology is designed to make the tumor more accessible to immune cells and other therapies, potentially improving the effectiveness of existing treatments.

Preclinical Research In Triple-Negative Breast Cancer

In a 2026 paper published in Molecular Cancer Therapeutics, Neobe worked with researchers from the University of Cyprus and Barts Cancer Institute in London.

The collaboration evaluated the company’s engineered bacterial platform in a model of triple-negative breast cancer that had not responded to a commonly used combination of immunotherapy drugs.

According to Neobe, a single dose of its engineered bacteria produced complete tumor regression in response to the same immunotherapy in one of the models studied.

When the model was exposed to the same cancer several months later, no additional tumors developed. The researchers said that result suggested the formation of lasting antitumor immune memory.

These findings were generated in preclinical models and do not establish that the approach will be safe or effective in people. NEO22 will need to complete additional laboratory studies and regulatory review before clinical testing can begin.

Laura Chow Joins As Chief Medical Officer

Neobe recently appointed immuno-oncology specialist Dr. Laura Chow as chief medical officer.

Chow will oversee clinical development and preparations for a first-in-human trial. Her appointment adds clinical leadership as the company moves from platform research toward the regulatory and operational requirements of human studies.

Neobe was founded in 2021 and is developing bacterial therapeutics intended to make treatment-resistant solid tumors more responsive to cancer medicines.

KEY QUOTES:

Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed. I’m delighted to be working with investors that share our vision of making untreatable cancers curable, and excited to move our platform towards clinical trials.

Dr. Pedro Correa de Sampaio, Co-Founder and CEO of Neobe Therapeutics

We are excited to back Neobe Therapeutics’ differentiated approach to overcoming the physical barriers created by dense tumour matrices. Assets derived from Neobe’s platform will improve the efficacy of cancer therapies and extend their benefits to more patients.

Joseph Korff, Founder of ARC Ventures

At Macmillan Ventures, we are working alongside people who are living with cancer today, to help shape the cancer care of tomorrow. Together, we want to break down barriers – to treatment, to care and in this case, the barrier that stands between a cancer and a treatment that could cure it. We are very proud to be supporting Neobe, and to be helping create the right environment for such promising new cancer care solutions to thrive.

Felix Litzkow, Head of Macmillan Ventures

2048 Ventures is proud to have supported Neobe since their pre-seed. The mission of Neobe and its founders has always resonated with us, which is to make life-saving drugs available and effective for all patients, regardless of the tumour microenvironment. We’re thrilled to continue working with Neobe and the current syndicate toward making that vision a reality.

Dr. Julie Wolf, Partner at 2048 Ventures